About HLK
Management Members


Ms. Jun Xu,  President

15 years of experience in drug discovery and development in multi-national pharmaceutical companies (Novartis,Boehringer Ingelheim)

 Responsible for various discovery and development projects

          Resposible for operation and business development ; US pharma business with Chinese pharma companies

 




Dr. Zeren Wang,  CSO

 Zeren is now the Managing Director and CSO of HLK. In this position, he is responsible for the  overall science and technical management of the company. Prior to this position, Zeren was the  Director, Formulation Development, at Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT.  In this role, he provided strategic leadership to a team focused on formulation and process  development of NCE products. Zeren was also responsible for organizational excellence, strategic planning of resources, budgets, career development of team members, and alignment with international counterparts. From 2009 to 2010, he also was the interim department head of Pharmaceutics. During his career at Boehringer Ingelheim Pharmaceuticals Inc, he managed process development, scale up, and technology transfer for submission of Aptivus capsules and Aptivus liquid formulations. He also was responsible for Process Technology, Physical Pharmaceutics, Materials Characterization, etc. Zeren is specialized in formulation development of poorly water soluble compounds for oral delivery and experienced in the development of oral solid dosage forms (tablets, hard gelatin capsules, soft gelatin capsules), oral liquid dosage forms (solutions and suspensions), controlled release technology, and parenterals (lyophilization). Under his leadership, his team introduced and implemented multiple new formulation technologies including SEDDS (self emulsifying drug delivery system) formulation technologies (soft gel and hard gel encapsulation capabilities), solid dispersion formulation technologies (spray drying and melt extrusion) as well as nano-milling. Prior to Boehringer Ingelheim Pharmaceuticals, he also worked at Novartis Pharmaceuticals and Eisai Inc. Zeren has 30 peerreviewed publications and patents, as well as numerous poster presentations. He received his PhD in Physical Pharmacy from University of Utah, Dr. William Higuchi’s lab.

 


 


Dr. Peter Farina,  Chairman of SAB

Dr. Peter Farina is an Executive in Residence at Canaan Partners, a venture capital firm, located in Westport, CT where he assesses and advises on pharma/biotech/healthcare investments. He is also the managing partner of a consulting firm, Salient Science & Technology, LLC which advises several biotech firms on strategic and technical matters in pharmaceutical R&D. Dr. Farina currently serves as the Co-Chair and Board Member of Connecticut United for Research Excellence (CURE); the Advisory Board of the University of Connecticut School of Pharmacy, member of the NIH Blueprint Neurotherapeutics Network (BPN) steering committee; Emory University DRIVE Advisory Board, and was a Founder and CEO of Developing World Cures, a nonprofit company working on neglected diseases.

Dr. Peter Farina retired in 2008 as Senior Vice President of Development at Boehringer Ingelheim Pharmaceuticals, Inc. in Ridgefield, CT where he was responsible for North American development of drugs in the therapeutics areas of Immunology/Inflammation, Virology and Cardiovascular Disease. During his tenure as SVP at BI, his interdisciplinary team worked on the development and successful registration of Aptivus, an HIV protease inhibitor, Viramune XR for HIV and Atrovent HFA for COPD and emphysema. Prior to this position he served as Vice President of Research at the Ridgefield Center. He has also held positions as Director of Inflammatory Diseases and Director of Biochemistry over his 28 year career with Boehringer Ingelheim. Prior to joining BI he spent 6 years in the Corporate Research Laboratories and Medical Products Division of Union Carbide Corporation in Tarrytown, NY where he did research and development of immunodiagnostics. Dr. Farina’s research interest has been generally at the interface of chemistry and biology. He has worked over his research career in inflammatory and immunological mechanisms, particularly cytokines and arachidonic acid mediators. In addition, he was engaged in HIV virology research which led to discovery and successful registration of one of the first non-nucleoside reverse transcriptase inhibitors Viramune(nevirapine). He is the author of over fifty publications and patents.

Dr. Farina has a PhD in organic chemistry from SUNY Buffalo and did postdoctoral work in bioorganic chemistry at Pennsylvania State University with Dr. Stephen Benkovic.

 


 

 

Dr. Susan Froshauer

  Former CEO of Connecticut United Research Excellence 

                Entrepreneur in Residence at Yale Entrepreneurial Institute, Yale University

                Board member of University of Connecticut Investment

                Consultant for Iron Ventures

                Rib-X Pharmaceuticalsfounder CEO10 years

                           Manager of Business Development, Pfizer

 


 


Dr. Yijun Cheng

 Oncologist, Buffalo Medical Group 


          Cancer biology PhD at the University of Texas MD Anderson Cancer Center 


          Board certified in Internal Medicine, Oncology and Hematology, Member of American College of 


          Physicians, American Society of Clinical Oncology, American Society of Hematology


          Broad experience in clinical research


                                        Consultant of multiple multinational pharmaceutical companies



 

Tel: +86-755-86007001   Email: info@hlkpharma.com